Skip to content

Yoga During Chemotherapy Study

Developing a Yoga Intervention During Cancer Chemotherapy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02442635
Enrollment
73
Registered
2015-05-13
Start date
2015-05-31
Completion date
2019-10-01
Last updated
2019-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Fatigue, Sleep Disturbance

Brief summary

This proposal aims to expand non-pharmacologic options for the control of symptoms during chemotherapy using yoga practices. It is particularly focused on sleep disturbance with a secondary focus on fatigue.

Detailed description

Sleep disturbance is among the most common symptoms experienced by cancer patients, occurs in up to 80% of patients during chemotherapy, and results in serious impairments in quality of life. Although pharmacologic therapies improve sleep disturbance, they have numerous side effects, problems with tolerance and dependence, and are not well studied in oncology patients. While non-pharmacologic therapies may decrease sleep disturbance, the current level of evidence on their efficacy is insufficient. Fatigue occurs in up to 95% of those receiving chemotherapy, and results in major impairments in functioning and quality of life. Despite its significance, few effective treatments currently exist for fatigue. Prior studies suggest that yoga may be helpful for sleep disturbance and fatigue, but these studies have limitations. An important challenge in yoga research is that it is typically a multi-modality practice that can include physical postures, breathing practices, and/or meditation components. Prior studies have not adequately addressed the effects of individual components. Therefore, key questions remain unanswered about the most effective elements of yoga; how to best combine them for particular problems such as chemotherapy symptoms; and optimal dosing. The current study will address these gaps in the literature and perform key developmental steps to prepare for a large randomized, controlled trial (RCT). It builds on preliminary work in which yoga breathing practices during chemotherapy were found to improve sleep disturbance, showed trends toward improvements in fatigue, and were feasible to implement in patients undergoing chemotherapy. Using a mixed-methods approach to evaluate each intervention component, the investigators will pursue three closely interlinked steps in cancer patients receiving chemotherapy. In Aim 1 (n=10), the investigators will manualize an individualized approach to the yoga breathing intervention and iteratively refine it to insure feasibility and acceptability. In Aim 2 (n=20), the investigators will manualize a yoga posture intervention, evaluating both restorative/static poses and flowing poses, and perform iterative refinement to test feasibility and acceptability. In Aim 3 (n=70), the investigators will assess the final multi-modality yoga intervention to select final intervention elements and delivery methods for testing in a planned future RCT. This proposal will help to improve the treatment of debilitating cancer associated symptoms and advance approaches to developing therapeutic yoga intervention trials.

Interventions

BEHAVIORALYoga

Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 and older * Have a Karnofsky Performance Status Score of 60 or above * Diagnosed with any cancer except acute leukemia * Self-reported poor quality of sleep * Receiving Chemotherapy * Able to read, write, and understand English * Ability to give informed consent

Exclusion criteria

* Diagnosed with brain metastasis * Diagnosed with severe Chronic Obstructive Pulmonary Disease (COPD) or emphysema * Have New York Heart Association class II or greater congestive heart failure * Requiring chronic home oxygen therapy * Diagnosed with a sleep disorder (e.g., sleep apnea or narcolepsy) * Have received more than 3 prior chemotherapy regimens * Receiving radiation therapy * Has a less than 6 month life expectancy * Regular yoga practice within the last 2 months

Design outcomes

Primary

MeasureTime frame
Sleep Disturbance as measured by the General Sleep Disturbance Scale6 weeks

Secondary

MeasureTime frame
Fatigue as measured by the Lee Fatigue Scale6 weeks

Other

MeasureTime frame
Anxiety as measured by the Spielberger State Anxiety Inventory6 weeks
Pain as measured by the modified Brief Pain Inventory6 weeks
Hot Flashes as measured by the Hot Flash Related Daily Interference Scale6 weeks
Quality of Life as measured by the Multidimensional Quality of Life Scale--Cancer6 weeks
Body Awareness as measured by the Multidimensional Assessment of Interoceptive Awareness6 weeks
Coping and Self Efficacy as measured by the Coping and Self Efficacy Scale6 weeks
Social Support as measured by single items on social support6 weeks
Mindfulness as measured by the Five Facet Mindfulness Questionnaire6 weeks
Depressive Symptoms as measured by the CES-D6 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026